04/03/2021 5:58 am Welcome to isteroids.com - BLOG

Monday 22, Feb 2010

  MS drug and steroids can redefine treatment by reducing disease activity

Posted By
Pin it Share on Tumblr

MS drug and steroids can redefine treatment by reducing disease activityDisease activity related with multiple sclerosis (MS) is reduced to a considerable extent when a combination of steroid drugs and MS drug is administered to patients, as per a study presented as a part of the Late-breaking Science Program at the American Academy of Neurology’s 61st Annual Meeting in Seattle.

Study author Mads Ravnborg, MD, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark, said that the study noted that both the drugs seem to have a synergy when taken together for providing improved beneficial effect on the disease activity as against use of the MS drug in isolation.

Monday 14, Dec 2009

  Steroid drugs added to MS treatment can reduce disease activity

Posted By
Pin it Share on Tumblr

Steroid drugs added to MS treatment can reduce disease activityThe addition of a steroid drug, methylprednisolone, to the multiple sclerosis (MS) drug can significantly reduce the amount of disease activity more than what could have been experienced with the use of MS drug in isolation, as per a presented study as part of the Late-breaking Science Program at the American Academy of Neurology’s 61st Annual Meeting in Seattle.

The study results clearly suggest that the two drugs, steroid and MS, can bring synergy when taken as a combination and provide a greater beneficial effect on the disease activity than MS drug alone, according to study author Mads Ravnborg, MD, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark.

 

 

 



Monday 30, Nov 2009

  Addition of steroids drugs to MS treatment can reduce disease activity

Posted By
Pin it Share on Tumblr

Addition of steroids drugs to MS treatment can reduce disease activity  When steroid drugs are added to multiple sclerosis (MS) treatment, the risk of disease activity gets reduced to a considerable extent as per a study presented as a part of the Late-breaking Science Program at the American Academy of Neurology’s 61st Annual Meeting in Seattle.

It was remarked by study author Mads Ravnborg, MD, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark, that results of this study highlight the fact that the two drugs tend to bring synergy in a combination and provide an improved beneficial effect on the disease activity as against use of the MS drug in isolation.